When was TeselaGen founded?

TeselaGen was founded in 2011 and raised its 1st funding round 1 year after it was founded.

Where is TeselaGen located?

TeselaGen is headquartered in San Francisco, United States.

How many employees does TeselaGen have?

As of Aug 31, 2026, the latest employee count at TeselaGen is 28.

Is TeselaGen a funded company?

TeselaGen is a funded company, having raised an undisclosed amount across 4 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jun 13, 2012.

When was the latest funding round of TeselaGen?

TeselaGen's latest funding was a $***** Grant (prize money) round on Oct 01, 2014, with participation from 0 investor.

Where does TeselaGen rank among its competitors?

TeselaGen ranks 184th amongst 505 active competitors, of which 173 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of TeselaGen?

TeselaGen's top competitors include Ginkgo Bioworks, Syngenta and Spark Therapeutics. Among them, Antheia secured the most recent funding round in January, 2026.

TeselaGen - 2026 Company Profile, Team, Funding & Competitors

Company Details

Cloud-based solution for combinatorial gene design and editing. TeselaGen is building a rapid prototyping system for fast bio-based construction of sustainably sourced chemicals, therapeutic medicines, and novel vaccines. It provides tools for sequence viewing, editing, and management; and combinatorial design, and system protocol generation for single or combinatorial DNA design. Their customers are biopharma and big industrial companies like Amgen and Genomatica. Their bioCAD/CAM system is based on technology licensed from Lawrence Berkeley National Lab and is being beta tested by users.

Website: teselagen.com
Social

Key Metrics

Founded Year

2011

Location

San Francisco, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Oct 01, 2014, $*****

Investors

Baruch Future Ventures & 3 more

Ranked

184^th among 505 active competitors

Employee Count

28 as on Aug 31, 2026

Similar Companies

Ginkgo Bioworks & 416 more

View TeselaGen's full profile

TeselaGen has raised funding over 4 rounds. Its first funding round was on Jun 13, 2012. TeselaGen has 4 institutional investors.

Here is the list of recent funding rounds of TeselaGen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 01, 2014	4115622	Grant (prize money)	6070361	7452582	6535267	1737047
Jan 01, 2013	7519221	Grant (prize money)	8123162	2210046	4585213	National Science Foundation
Jul 01, 2012	7331651	Grant (prize money)	3706955	5186899	7923163	National Science Foundation

Access funding benchmarks and valuations. Sign up today!

View details of TeselaGen's funding rounds and investors

The founders of TeselaGen is Eduardo Abeliuk.

Here are the details of TeselaGen's key team members:

Eduardo Abeliuk: Founder of TeselaGen.

View details of TeselaGen's Founder profiles and Board Members

TeselaGen's employee count trend

TeselaGen has 28 employees as of Aug 26. Here is TeselaGen's employee count trend over the years:

Uncover TeselaGen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of TeselaGen include Ginkgo Bioworks, Syngenta and Spark Therapeutics. Here is the list of Top 10 competitors of TeselaGen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Ginkgo Bioworks 2008, Boston (United States), Public	Autonomous labs for biotechnology, empowering scientists to design the living world	$796M	Viking Global Investors, T. Rowe Price & 53 others	81/100
2nd	Syngenta 2000, Basel (Switzerland), Acquired	Developer of technologies and sustainable farming practices for farmers	-	Analah Ventures, Europa	75/100
3rd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
4th	Twist Bioscience 2013, San Francisco (United States), Public	Developer of a semiconductor-based DNA synthesis platform	$321M	Foresite Capital, Fidelity Investments & 39 others	72/100
5th	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	Redmile Group, Cormorant-asset & 16 others	70/100
6th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
7th	Codexis 2002, Redwood City (United States), Public	Developer of high-performance enzymes for drug discovery	$111M	Vivo Capital, Malaysian Life Sciences Capital Fund ... & 12 others	68/100
8th	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Vida Ventures, TPG & 4 others	68/100
9th	CureVac 2000, Tubingen (Germany), Acquired	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	Dievini, Gates & 16 others	67/100
10th	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
184th	TeselaGen 2011, San Francisco (United States), Funding Raised	Cloud-based solution for combinatorial gene design and editing	-	Baruch Future Ventures, National Science Foundation ... & 2 others	36/100